Non-small-cell lung cancer (NSCLC) treatment has led to improved efficacy and compliance due to individual tailoring of the therapeutic options and the use of strategies based on both clinical ...

Peters, of the Centre Hospitalier Universitaire Vaudois in Lausanne, Switzerland, described the importance of checkpoint inhibitors in the management of advanced NSCLC without actionable genomic ...

Panel Introduction This summary is based on an AJMC Peer Exchange program titled “Advancing ALK+ NSCLC Care: Optimizing Treatment, Sequencing, and Long-Term Outcomes,” featuring the following ...

Deferring CNS-directed radiation therapy in EGFR-variant and ALK-positive NSCLC with brain metastases improves outcomes but increases treatment-related toxicity. Up-front stereotactic radiosurgery ...

In the Phase III HARMONi-6 trial, ivonescimab plus chemotherapy significantly outperformed tislelizumab plus chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer.

Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE ...

Prior to HARMONi-6, there were no known Phase III clinical trials in NSCLC which have shown a statistically significant improvement compared to PD-(L)1 inhibitor therapy in combination with ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European Commission (EC) to treat resectable non-small cell lung cancer (NSCLC). The ...